| BioRestorative Therapies is a life sciences company focused on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult stem cells. Co.'s cell therapy candidate, BRTX-100, is a product formulated from autologous (or person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. Co. is developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue. Co. has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. The BRTX YTD return is shown above.
The YTD Return on the BRTX YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether BRTX YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BRTX YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.